logo-loader
HealthPharma & Biotech
ANGLE PLC

ANGLE device central to new, ground-breaking cancer research

Scientists at the University of Basel, Switzerland, used ANGLE’s Parsortix liquid biopsy to isolate metastatic circulating tumour cell clusters

cancer cells from taken by an electron microscope
The work may ultimately help prevent the spread of the killer disease, a process called metastasis

ANGLE PLC (LON:AGL) has revealed its cancer detection device played an important role in research that may one day help prevent the spread of cancer around the body.

Scientists at the University of Basel, Switzerland, used ANGLE’s Parsortix liquid biopsy to isolate metastatic circulating tumour cell clusters - a group of cancer and other cells tethered together as a single mass.

WATCH: ANGLE plc's Parsortix device plays critical role in ground-breaking new cancer research

Once these clusters were identified, the Basel team, led by Professor Nicola Aceto, was able to treat them with repurposed drugs already on the market.

Eye-catching

Eye-catching was the fact that this approach led to a “near total elimination” of metastasis in animal models.

As most people will know, metastasis is where cancer spreads to other parts of the body via the bloodstream. It is responsible for more than 90% of all cancer-related deaths.  

The detail of the research undertaken by the Cancer Metastasis Laboratory was published Friday (Jan 11) as a peer-reviewed article in the prestigious journal, Cell.

ANGLE is seeking US Food & Drug Administration approval for Parsortix.

Ground-breaking

Chief executive, Andrew Newland, said: "The ground-breaking CTC cluster work undertaken over the last three years by the University of Basel, one of ANGLE's leading customers, highlights completely new clinical uses for the Parsortix system with the potential to play a central role in dramatically improving patient outcomes.

“This is a key potential application for Parsortix liquid biopsy once we receive FDA clearance.

“Our ultimate aim is for the Parsortix system to be routinely used for all cancer patients in the future."

---Repeated from Thursday evening---

Quick facts: ANGLE PLC

Price: £0.71

Market: AIM
Market Cap: £122.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Angle’s Newland reflects on excellent year as cancer patient trials advance

Angle Plc (LON:AGL, OTCMKTS:ANPCY) is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland. As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of...

on 07/28/2016

2 min read